ArticleScientific reports2025
Enhancer RNAs contribute to genome reprogramming driven by a GATA3 noncoding variant in leukaemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The GATA3 noncoding variant rs3824662 has been implicated in the pathogenesis of Ph-like B-ALL, where it is associated with extensive chromatin reorganisation, resulting in the dysregulation of multiple genes, including CRLF2 overexpression. Given the altered chromatin landscape and increased accessibility of GATA3 binding regions associated with the rs3824662 variant, we investigated the potential role of enhancer RNAs (eRNAs) located near the GATA3 locus in regulating CRLF2 expression. We found that the expression of eRNA_G3, located at chr10:8,443,562-8,449,563, was positively correlated with CRLF2 expression. Notably, eRNA_G3 was significantly upregulated in Ph-like ALL cases carrying the GATA3 rs3824662 variant. These findings suggest that both rs3824662 and eRNAs may cooperatively contribute to the regulatory mechanisms governing GATA3 and CRLF2 expression in Ph-like ALL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.